STOCK MARKET BSE NSE

National COVID-19 fatality rate is 2.6 per cent and it is coming down rapidly: Health Ministry

On COVID testing, he said that 22 states are currently performing more than 140 tests per day per million population.

Published: 14th July 2020 08:01 PM  |   Last Updated: 15th July 2020 11:17 AM   |  A+A-

OSD at the Ministry of Health Rajesh Bhushan addresses a press conference in New Delhi Tuesday July 14 2020.

OSD at the Ministry of Health Rajesh Bhushan addresses a press conference in New Delhi Tuesday July 14 2020. (Photo | PTI)

By Express News Service

NEW DELHI: The Centre on Tuesday said 50 per cent Covid-19 cases are from just two states, Maharashtra and Tamil Nadu, while 10 states have 86 per cent of the total active cases in India.

As on Monday, India had 3,11,565 active coronavirus cases with 1,54,134 of those patients in Maharashtra and Tamil Nadu.

The rest 8 states which have 36 per cent of the case load include Karnataka, Delhi, Andhra Pradesh, Uttar Pradesh, Telangana, West Bengal, Gujarat and Assam.

Rajesh Bhushan, officer on special duty in the Ministry of Health and Family Welfare, said 22 states are doing more than 140 per million tests per day.

For India as a whole, the testing rate per million per day stands at 201. Bhushan said while the daily growth rate of the cases was 31 per cent in March, it is just above 3 now.

ALSO READ: India 'pharmacy of the world', on fast-track mode to develop COVID-19 vaccine, says ICMR

Meanwhile, ICMR director general Dr Balram Bhargava,  who drew  huge criticism a few days back for setting August 15 deadline for Covid-19 vaccine launch, cited instances of other countries where vaccine development has been fast-tracked and said it is “our moral duty to launch the vaccine at the earliest”.

Responding to a query on exemption from phase 3 trial to the drug itolizumab by the country’s drug regulator, he said while two drugs, tocilizumab and itolizumab, are thought to prevent cytokine storms — a complication due to Covid-19 — none have yet shown any benefit in terms of mortality due to the disease.

He said randomised control trials with these drugs are being conducted in various countries to assess if they can help reduce Covid fatalities.

Biocon, which manufactures itilozumab under the brand name Alzumab, on Monday cited data from phase 2 trial with 30 patients and had said while 3 out of 10 patients in the control arm, without the drug had succumbed to the disease, none with the medicine died in the intervention group.

Stay up to date on all the latest Nation news with The New Indian Express App. Download now

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp